H.C. Wainwright initiates Senti Biosciences with 'Buy' on cell therapy hopes

Senti Biosciences Holdings

14/10/2025 14:07

** Shares of cancer therapies developer Senti Biosciences SNTI.O rise 1.1% to $1.70 in premarket

** H.C. Wainwright starts coverage with "Buy" rating and price target $12, a ~614% upside to the stock's last close

** Brokerage says Senti's new cell therapy helped patients with tough-to-treat blood cancer

** It believes co's therapy platform "has the potential to treat several cancer types, including hematologic malignancies and solid tumors"

** SNTI is developing a cell therapy to treat acute myeloid leukemia, a fast-growing blood cancer with limited treatment options

** 2 of 2 brokerages rate the stock 'buy' or higher, none 'hold' or 'sell'; their median price target is $13.50

** Up to last close, stock has fallen ~52% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))